UCL logo

UCL Discovery

UCL home » Library Services » Electronic resources » UCL Discovery

Antithrombotic treatment failures in antiphospholipid syndrome: the new anticoagulants?

Cohen, H; Machin, SJ; (2010) Antithrombotic treatment failures in antiphospholipid syndrome: the new anticoagulants? LUPUS , 19 (4) 486 - 491. 10.1177/0961203310361355.

Full text not available from this repository.

Abstract

Anticoagulation with oral vitamin K antagonists (VKA) is the mainstay of the treatment of venous and/or arterial thromboembolism in patients with antiphospholipid syndrome (APS), although the optimal intensity of anticoagulation remains controversial. The limitations of existing anticoagulants have driven a search for novel agents. Dabigatran etexilate (Pradaxa (R)), a direct thrombin inhibitor (DTI), and rivaroxaban (Xarelto (R)), the first in a new class of drugs, the oral direct factor Xa (FXa) inhibitors, are both fixed-dose orally administered agents. They are now licensed in the UK and Europe for the prevention of venous thromboembolism (VTE) in adult patients undergoing elective total hip replacement (THR) or total knee replacement (TKR). Prospective randomized clinical trials suggest that these agents, and also apixaban, a further oral direct anti-Xa inhibitor, may have potential in other areas including the treatment of acute VTE, prevention of stroke or systemic embolism in patients with atrial fibrillation (AF) and acute coronary syndromes. Here, we summarize current indications for these agents and address the potential for their use in patients with thrombotic APS. Lupus (2010) 19, 486-491.

Type: Article
Title: Antithrombotic treatment failures in antiphospholipid syndrome: the new anticoagulants?
DOI: 10.1177/0961203310361355
Keywords: Dabigatran, Rivaroxaban, Antiphospolipid syndrome, Thrombosis, arterial, venous, TOTAL KNEE ARTHROPLASTY, VENOUS THROMBOEMBOLISM, DABIGATRAN ETEXILATE, TOTAL HIP, RECURRENT THROMBOSIS, LUPUS ANTICOAGULANT, ANTIBODY-SYNDROME, RANDOMIZED-TRIAL, DOUBLE-BLIND, PREVENTION
UCL classification: UCL > Provost and Vice Provost Offices
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute > Research Department of Haematology
URI: http://discovery.ucl.ac.uk/id/eprint/1331450
Downloads since deposit
0Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item